Mahyar Etminan1, Sudeep Gill, Ali Samii. 1. Department of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A1. mahyar.etminan@mail.mcgill.ca
Abstract
OBJECTIVES: To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use. DESIGN: Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease. Studies identified through Medline, Embase, International Pharmaceutical Abstracts, and the Cochrane Library. RESULTS: Nine studies looked at all NSAIDs in adults aged > 55 years. Six were cohort studies (total of 13 211 participants), and three were case-control studies (1443 participants). The pooled relative risk of Alzheimer's disease among users of NSAIDs was 0.72 (95% confidence interval 0.56 to 0.94). The risk was 0.95 (0.70 to 1.29) among short term users (< 1 month) and 0.83 (0.65 to 1.06) and 0.27 (0.13 to 0.58) among intermediate term (mostly < 24 months) and long term (mostly > 24 months) users, respectively. The pooled relative risk in the eight studies of aspirin users was 0.87 (0.70 to 1.07). CONCLUSIONS: NSAIDs offer some protection against the development of Alzheimer's disease. The appropriate dosage and duration of drug use and the ratios of risk to benefit are still unclear.
OBJECTIVES: To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use. DESIGN: Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease. Studies identified through Medline, Embase, International Pharmaceutical Abstracts, and the Cochrane Library. RESULTS: Nine studies looked at all NSAIDs in adults aged > 55 years. Six were cohort studies (total of 13 211 participants), and three were case-control studies (1443 participants). The pooled relative risk of Alzheimer's disease among users of NSAIDs was 0.72 (95% confidence interval 0.56 to 0.94). The risk was 0.95 (0.70 to 1.29) among short term users (< 1 month) and 0.83 (0.65 to 1.06) and 0.27 (0.13 to 0.58) among intermediate term (mostly < 24 months) and long term (mostly > 24 months) users, respectively. The pooled relative risk in the eight studies of aspirin users was 0.87 (0.70 to 1.07). CONCLUSIONS: NSAIDs offer some protection against the development of Alzheimer's disease. The appropriate dosage and duration of drug use and the ratios of risk to benefit are still unclear.
Authors: B A in 't Veld; L J Launer; A W Hoes; A Ott; A Hofman; M M Breteler; B H Stricker Journal: Neurobiol Aging Date: 1998 Nov-Dec Impact factor: 4.673
Authors: Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley Journal: J Neurochem Date: 2010-05-26 Impact factor: 5.372
Authors: Frédéric Calon; Giselle P Lim; Fusheng Yang; Takashi Morihara; Bruce Teter; Oliver Ubeda; Phillippe Rostaing; Antoine Triller; Norman Salem; Karen H Ashe; Sally A Frautschy; Greg M Cole Journal: Neuron Date: 2004-09-02 Impact factor: 17.173
Authors: Nicholas H Varvel; Kiran Bhaskar; Maria Z Kounnas; Steven L Wagner; Yan Yang; Bruce T Lamb; Karl Herrup Journal: J Clin Invest Date: 2009-11-09 Impact factor: 14.808